NCBiotech News

We work hard to bring you news about North Carolina’s wide-ranging life sciences community. Please feel free to share it with others. And let us know if you have something we should know about.

CiVentiChem has received its first U.S. Food and Drug Administration approval for a generic commercial active pharmaceutical ingredient (API) manufactured at its Cary headquarters.

With uncertain weather forecast, the NCBiotech RTP office is opening at noon on Wednesday February 20.

Many of us will be checking in from home. Please stay safe out there.

Glenmark Pharmaceuticals, the largest pharmaceutical manufacturer in the Greater Charlotte region, is bringing a big “Help Wanted” message to the North Carolina Biotechnology Center’s monthly Jobs Network event, in search of production employees to help meet its fast-growing demand.
Two Triangle scientists, including NCBiotech staff member Tracey du Laney, Ph.D., and Duke University researcher Kafui Dzirasa, Ph.D., M.D., are among 10 honored today with prestigious fellowships from the American Association for the Advancement of Science.
Syneos Health is joining the worldwide annual observance of Rare Disease Day, Thursday, February 28, by hosting a free public in-depth Rare Disease Day Symposium, from 11:30 a.m. to 3 p.m., at its new global headquarters in Morrisville.
Sapere Bio is a 6-year-old Research Triangle-based startup using biomarkers to predict biological age so people can stay healthy longer.
New entrants to the biomanufacturing industry recently described for an enthusiastic audience at an NCBiotech event that they're experiencing incredible opportunity, thanks to North Carolina's workforce training system and excellent pool of grateful employers.
RFPi, a Greenville medical device company that was bootstrapped with a loan from the North Carolina Biotechnology Center, has received clearance from the U.S. Food and Drug Administration to begin marketing its iCertainty blood flow and perfusion imaging device.
According to a report published by Xconomy, startups often look to San Francisco and Silicon Valley for the venture capital they need. But they don’t have to locate there to attract funding. And they might be wiser to consider a lower-cost region like the Raleigh-Durham area instead.
Actus Therapeutics of Chapel Hill has dosed the first patient in a phase 1/2 clinical study of its gene therapy in patients with Pompe disease, a rare genetic disorder that often leads to premature death in children and adults.
Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, will acquire the exclusive commercialization rights to a life-saving medical device for newborns facing a potentially deadly respiratory condition.
Pfeiffer University broke ground today for a $16 million Center for Health Sciences to be located on Main Street in Albemarle. It will house the school’s new Physician Assistant Studies and Occupational Therapy programs.
More than 150 people attending the Digital Health 360 Summit in Durham last month focused on three topics: identifying barriers to healthcare engagement, building healthy communities, and using digital technology to strengthen precision health in North Carolina.
Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to begin a study of its first clinical-stage product candidate, a cancer immunotherapy.
Precision health took center stage in North Carolina recently as Duke University hosted its second Precision Medicine World Conference (PMWC). The event attracted more than 400 experts who represented health and biotechnology organizations from around the world.
scroll back to top of page